Sermorelin
Stocked in 5mg, 10mg at MontanaPep in Great Falls, Montana. Sold for laboratory research use only.
| Size | Catalog no. | Price per vial |
|---|---|---|
| 5mg | SMO5 | $20 |
| 10mg | SMO10 | $35 |
Classification
GHRH(1-29) analogue; formerly FDA-approved, withdrawn for commercial reasons
Structure and chemistry
Sermorelin is GHRH(1-29) amide — the first 29 amino acids of human growth-hormone-releasing hormone, unmodified, with a C-terminal amide. This 29-residue fragment is the shortest portion of the 44-amino-acid parent hormone that retains full growth-hormone-releasing activity. Unlike CJC-1295 no-DAC (Mod GRF 1-29), sermorelin carries none of the stabilizing amino-acid substitutions, so it remains susceptible to rapid enzymatic degradation.
What the published research shows
Sermorelin is unusual among peptides in this catalog: it completed a full New Drug Application with clinical trial data and received FDA approval. Published research includes pediatric growth-hormone-deficiency trials from the late 1980s and 1990s and diagnostic validation work on pituitary somatotroph function.
Mechanism of action
A GHRH receptor agonist acting on anterior pituitary somatotrophs to stimulate synthesis and release of endogenous growth hormone. Because it works upstream through the pituitary, GH release remains subject to normal negative feedback from somatostatin and IGF-1, unlike administration of recombinant GH itself.
Development history
Developed as a truncated synthetic analogue of GHRH following the characterization of the parent hormone in the early 1980s, work that built on the Nobel Prize-winning hypothalamic hormone research of Roger Guillemin and Andrew Schally. It was brought to market by Serono Laboratories, later EMD Serono, under the brand names Geref and Geref Diagnostic.
Current regulatory status
Sermorelin holds a different regulatory position from most compounds in this catalog, and the distinction matters. It was genuinely FDA-approved, and when EMD Serono discontinued it in 2008 the reason was commercial, not safety — recombinant growth hormone had taken over the market. FDA formally withdrew the approvals effective June 18, 2009, and then in 2013 published a Federal Register determination that Geref was not withdrawn for reasons of safety or effectiveness. That determination is what allows sermorelin to be legally compounded under section 503A. It does not, however, mean any currently sold sermorelin product is FDA-approved — no approved sermorelin product exists in the US today. Notably, sermorelin has not been placed on FDA’s bulk drug substances lists.
Analytical testing
Identity should be confirmed against a certified GHRH(1-29) reference standard. Because sermorelin and Mod GRF 1-29 share the same 29-residue backbone and differ only by four substitutions, mass spectrometry is necessary to tell them apart; they are frequently confused and are not interchangeable.
Ordering from Great Falls
MontanaPep, also known as Montana Peptides, is an independently owned supplier based at 715 13th Ave S, Great Falls, Montana. Local pickup is available by arrangement, and we ship to research addresses across Montana including Billings, Missoula, Bozeman, Helena, Butte, Kalispell and Havre. Call (406) 799-0812 or email customerservice@montanapep.com.